EA201590260A1 - СОЕДИНЕНИЯ НА ОСНОВЕ ПЕПТИДОВ И ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ АККУМУЛЯЦИИ β-АМИЛОИДА - Google Patents

СОЕДИНЕНИЯ НА ОСНОВЕ ПЕПТИДОВ И ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ АККУМУЛЯЦИИ β-АМИЛОИДА

Info

Publication number
EA201590260A1
EA201590260A1 EA201590260A EA201590260A EA201590260A1 EA 201590260 A1 EA201590260 A1 EA 201590260A1 EA 201590260 A EA201590260 A EA 201590260A EA 201590260 A EA201590260 A EA 201590260A EA 201590260 A1 EA201590260 A1 EA 201590260A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
accumulation
peptides
applications
treatment
Prior art date
Application number
EA201590260A
Other languages
English (en)
Other versions
EA031902B1 (ru
Inventor
Владислав Дейгин
Ольга Вольпина
Наталья Бобкова
Original Assignee
Ооо "Фарма Био"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Фарма Био" filed Critical Ооо "Фарма Био"
Publication of EA201590260A1 publication Critical patent/EA201590260A1/ru
Publication of EA031902B1 publication Critical patent/EA031902B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящая заявка относится к новым соединениям на основе пептидов, необязательно содержащим иммуноактивный встроенный адъювант, к композициям, содержащим эти соединения, и к их применению, конкретно, для лечения заболеваний, расстройств или патологических состояний, характеризующихся или ассоциированных с аккумуляцией β-амилоида. Конкретно, настоящая заявка включает соединения формулы I и их композиции и применения
EA201590260A 2012-07-24 2013-07-24 СОЕДИНЕНИЯ НА ОСНОВЕ ПЕПТИДОВ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АККУМУЛЯЦИИ β-АМИЛОИДА EA031902B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261675205P 2012-07-24 2012-07-24
PCT/IB2013/056082 WO2014016787A2 (en) 2012-07-24 2013-07-24 Peptide-based compounds and uses thereof to treat beta-amyloid accumulation

Publications (2)

Publication Number Publication Date
EA201590260A1 true EA201590260A1 (ru) 2015-07-30
EA031902B1 EA031902B1 (ru) 2019-03-29

Family

ID=49997919

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590260A EA031902B1 (ru) 2012-07-24 2013-07-24 СОЕДИНЕНИЯ НА ОСНОВЕ ПЕПТИДОВ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АККУМУЛЯЦИИ β-АМИЛОИДА

Country Status (5)

Country Link
US (1) US9718869B2 (ru)
EP (1) EP2877486B1 (ru)
CA (1) CA2879943C (ru)
EA (1) EA031902B1 (ru)
WO (1) WO2014016787A2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574585B (zh) * 2019-01-30 2021-10-01 浙江省医学科学院 一种鳕鱼皮寡肽及其分离纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
AU2007280995C1 (en) * 2006-08-04 2013-05-23 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
RU2372355C1 (ru) * 2008-06-27 2009-11-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Пептид, обладающий защитным действием против болезни альцгеймера

Also Published As

Publication number Publication date
EA031902B1 (ru) 2019-03-29
CA2879943A1 (en) 2014-01-30
WO2014016787A2 (en) 2014-01-30
US9718869B2 (en) 2017-08-01
EP2877486A4 (en) 2016-08-24
WO2014016787A3 (en) 2015-07-30
EP2877486A2 (en) 2015-06-03
EP2877486B1 (en) 2019-05-01
CA2879943C (en) 2021-08-31
US20150337026A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201790413A1 (ru) Антитела против tigit
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
EA201690734A1 (ru) Ингибиторы бромодомена
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
EA201290919A1 (ru) Индазольные соединения и их применение
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201590562A1 (ru) Бензамиды
EA201491500A1 (ru) Способы лечения фиброза
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201201296A1 (ru) Способы лечения диабетических язв стопы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU